COVID-19-Induced Neuroinflammation Follows a Different Pathological Course Than Traditional Neurodegenerative Diseases

Medical News: A New Perspective on COVID-19’s Impact on the Brain
A groundbreaking study conducted by researchers from Saarland University-Germany, Stanford University-USA, Columbia University-USA, and Helmholtz Institute for Pharmaceutical Research-Germany has shed new light on how COVID-19-induced neuroinflammation follows a different pathological course compared to traditional neurodegenerative diseases like Parkinson’s disease (PD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB). The study offers insights into the unique ways SARS-CoV-2 affects brain tissue, leading to distinct inflammatory responses that could have even more serious long-term consequences.


COVID-19-Induced Neuroinflammation Follows a Different Pathological Course Than Traditional
Neurodegenerative Diseases

Distinguishing COVID-19-Related Brain Inflammation from Typical Neurodegeneration
For years, scientists have investigated the role of inflammation in neurodegenerative diseases, as conditions like Parkinson’s and dementia involve chronic neuroinflammatory processes. However, this Medical News report highlights a crucial finding - COVID-19 triggers a unique form of neuroinflammation that is distinctly different from the inflammation seen in these progressive brain disorders. The study utilized advanced spatial transcriptomics, analyzing over 1.5 million cells from the dorsolateral prefrontal cortex and anterior cingulate cortex of deceased COVID-19 patients and individuals with neurodegenerative diseases.
 
The researchers found that in COVID-19, the immune system’s response is rapid and highly aggressive, leading to widespread infiltration of peripheral immune cells into the brain’s white matter. In contrast, traditional neurodegenerative diseases involve a slower, more gradual process of chronic neuroinflammation without significant infiltration of external immune cells.
 
The Role of the Blood-Brain Barrier and Peripheral Immune Cells
One of the most striking differences observed in COVID-19 patients was the extensive disruption of the blood-brain barrier (BBB). The study found that endothelial cells in the brain were highly inflamed, displaying increased expression of inflammatory markers such as CSF3, CCL2, and SPP1. This inflammation led to significant permeability of the BBB, allowing peripheral immune cells - macrophages and monocytes - to infiltrate brain tissue.
 
In comparison, in diseases like Parkinson’s and dementia, neuroinflammation is primarily driven by resident brain immune cells, such as microglia and astrocytes, which become overactive over time. The absence of peripheral immune cell infiltration in neurodegenerative diseases further emphasizes the distinct pathological mechanisms at play in COVID-19-related brain inflammation.
 
Reactive Astrogliosis and Metabolic Stress in COVID-19
Another key finding of the study was the widespread presence of reactive astrogliosis in COVI D-19 patients, a condition in which astrocytes - key support cells in the brain - become hyperactive due to extreme stress. This was evident in the high expression of GFAP and mitochondrial genes such as MT-ND2, MT-ND3, and MT-ND5. The presence of these metabolic stress markers suggests that SARS-CoV-2 infection places immense energy demands on brain cells, leading to cellular exhaustion and potential long-term neurological damage.
 
Interestingly, the study also found elevated expression of hemoglobin-related genes (HBA1, HBA2, HBB) in the brain tissue of COVID-19 patients. This unusual observation could indicate microhemorrhages or disruptions in oxygen transport within brain tissue, possibly contributing to the neurological symptoms seen in severe cases of COVID-19.
 
Suppression of Neuroprotective Mechanisms
Another crucial difference between COVID-19-induced neuroinflammation and traditional neurodegenerative diseases was the suppression of neuroprotective mechanisms. In neurodegenerative diseases, the brain attempts to counteract damage by activating regenerative pathways that promote neuronal survival and repair. However, in COVID-19, these protective pathways were found to be severely downregulated in areas where immune cell infiltration was most intense.
 
By analyzing spatial transcriptomic gradients, the researchers found that inflammatory pathways dominated in areas of immune infiltration, while neuroprotective genes related to nervous system development and axonogenesis were significantly suppressed. This suggests that COVID-19’s neuroinflammatory response may actively inhibit the brain’s ability to repair itself, potentially contributing to long-term cognitive impairment in survivors.
 
Implications for Long COVID and Future Research
The findings of this study provide important implications for understanding and addressing long COVID, a condition in which individuals experience lingering neurological symptoms such as brain fog, memory loss, and fatigue for months after recovering from the initial infection. The presence of persistent immune cell infiltration, BBB dysfunction, and metabolic stress markers in COVID-19 brain tissue suggests that long-term neuroinflammation could be a driving force behind these prolonged symptoms.
 
Furthermore, these results emphasize the need for targeted treatments that specifically address the unique neuroinflammatory pathways triggered by COVID-19. Potential therapeutic approaches could involve strategies to restore blood-brain barrier integrity, reduce peripheral immune cell infiltration, and promote neuroprotective mechanisms.
 
Conclusion: Why COVID-19 Neuroinflammation is More Worrisome
Unlike traditional neurodegenerative diseases that develop slowly over years, COVID-19-induced neuroinflammation occurs rapidly and involves an acute breach of the blood-brain barrier. This results in an overwhelming influx of peripheral immune cells, causing severe inflammation that suppresses the brain’s natural repair mechanisms. Additionally, the metabolic stress placed on neurons and astrocytes may accelerate neuronal dysfunction, potentially leading to long-term cognitive deficits even in individuals who recover from the acute infection.
 
The uniqueness of COVID-19-induced neuroinflammation lies in its aggressive nature and the inability of the brain to mount an effective regenerative response. While neurodegenerative diseases like Parkinson’s and dementia involve chronic inflammation confined to the brain’s resident immune system, COVID-19 introduces an entirely new inflammatory profile that could have significant consequences for global neurological health in the coming years.
 
Understanding these differences is crucial for developing effective treatments and interventions, particularly as the world continues to grapple with the long-term neurological effects of SARS-CoV-2.
 
The study findings were published on a preprint server and are currently being peer-reviewed.
https://www.biorxiv.org/content/10.1101/2025.03.15.643484v1
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/covid-19-causes-the-upregulation-of-neuroinflammation-associated-genes-in-the-brain
 
https://www.thailandmedical.news/news/neuroinflammation-in-the-brainstem-and-its-link-to-pots-and-long-covid
 
https://www.thailandmedical.news/news/long-covid-brain-inflammation-could-be-the-hidden-cause-of-cognitive-decline-and-mental-hea
 
https://www.thailandmedical.news/articles/coronavirus
 
https://www.thailandmedical.news/pages/thailand_doctors_listings